Thu Dec 9, 2010 1:27pm GMT
* Teva hopes for U.S. regulatory green light in 2 years
* Teva developing laquinimod drug with Active Biotech
* Laquinimod a rival to new Novartis pill Gilenya
JERUSALEM, Dec 9 (Reuters) – Teva Pharmaceutical Industries expects its pill-based treatment for multiple sclerosis to receive U.S. regulatory approval within two years after a clinical trial met its main goal, it said on Thursday.
Laquinimod, being developed with Sweden’s Active Biotech , is jockeying for position in the emerging field of oral treatments for multiple sclerosis (MS), where Novartis’s recently approved Gilenya is the current leader.
****************************************************************
If you find our information valuable,
****************************************************************
“Providing You with ‘MS Views and News’, is what we do“
Keep Informed and up–to–date with information concerning
Multiple Sclerosis when registered at
the MS Views and News website.
****************************************************************
Disclaimer: ‘MS Views and News’ (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
. ****************************************************************
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews